Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status

Current treatment modalities for disseminated cutaneous malignant melanoma (CMM) improve survival; however, relapses are common. A number of receptor tyrosine kinases (RTKs) including EGFR and MET have been reported to be involved in CMM metastasis and in the development of resistance to therapy, ta...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cell Death Dis
Huvudupphovsmän: Das, Ishani, Wilhelm, Margareta, Höiom, Veronica, Franco Marquez, Rodolfo, Costa Svedman, Fernanda, Hansson, Johan, Tuominen, Rainer, Egyhàzi Brage, Suzanne
Materialtyp: Artigo
Språk:Inglês
Publicerad: Nature Publishing Group UK 2019
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6737096/
https://ncbi.nlm.nih.gov/pubmed/31506424
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-019-1875-8
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk